DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB

Phase 3

Completed

Conditions: Hepatitis B Virus

Interventions: Drug: Telbivudine plus tenofovir
Drug: Telbivudine
Drug: Tenofovir

First Posted Date: 2008-12-10

Last Posted Date: 2012-02-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 83

Registration Number: NCT00805675

Locations: 🇨🇳
Department of Medicine, Queen Mary Hospital, Hong Kong, China

Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis

Phase 2

Completed

Conditions: Chronic Plaque Psoriasis

Interventions: Drug: AIN457
Drug: Placebo

First Posted Date: 2008-12-09

Last Posted Date: 2015-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 130

Registration Number: NCT00805480

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib

Phase 3

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: nilotinib
Drug: imatinib

First Posted Date: 2008-12-05

Last Posted Date: 2015-11-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 191

Registration Number: NCT00802841

Locations: 🇻🇪
Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela

An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: Zoledronic acid
Drug: Placebo

First Posted Date: 2008-11-27

Last Posted Date: 2020-09-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT00799266

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Indacaterol 300 μg capsules
Drug: Indacaterol 150 μg capsules
Drug: Placebo capsules

First Posted Date: 2008-11-19

Last Posted Date: 2011-08-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 347

Registration Number: NCT00794157

Locations: 🇯🇵
Novartis Investigative site, Tokyo, Japan
🇨🇳
Novartis Investigator Site, Taipei, Taiwan
🇨🇳
Novartis Investigative Site, Taipei, Taiwan

and more 1 locations

Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Indacaterol 150 µg
Drug: Indacaterol 300 μg
Drug: Placebo to indacaterol

First Posted Date: 2008-11-18

Last Posted Date: 2011-08-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 563

Registration Number: NCT00792805

Locations: 🇨🇳
Novartis Investigator Site, Fuzhou, China
🇮🇳
Novartis Investigative Site, Trivandrum, India

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Phase 1

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: Lapatinib in combination with an anti-cancer agent
Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Drug: Lapatinib

First Posted Date: 2008-11-14

Last Posted Date: 2018-02-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 500

Registration Number: NCT00790816

Locations: 🇪🇸
Novartis Investigative Site, Hospitalet de Llobregat (Barcelona), Spain

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Phase 3

Completed

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Everolimus
Drug: Everolimus Placebo

First Posted Date: 2008-11-13

Last Posted Date: 2017-07-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 742

Registration Number: NCT00790036

Locations: 🇺🇸
Medical University of South Carolina -Hollings Cancer Center MUSC/HCC (2), Charleston, South Carolina, United States
🇺🇸
Ironwood Cancer and Research Centers SC, Chandler, Arizona, United States
🇺🇸
Levine Cancer Institute Oncology, Charlotte, North Carolina, United States

and more 32 locations

Phase II Study of TKI258 in Advanced Urothelial Carcinoma

Phase 2

Completed

Conditions: Urothelial Cancer

Interventions: Drug: TKI258

First Posted Date: 2008-11-13

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT00790426

Locations: 🇺🇸
USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3, Los Angeles, California, United States
🇺🇸
University Chicago Hospital CTKI258A2201, Chicago, Illinois, United States
🇺🇸
Duke University Medical Center Dept.ofDukeUniversityMedCtr(2), Durham, North Carolina, United States

and more 6 locations

Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)

Phase 3

Completed

Conditions: Tuberous Sclerosis
Subependymal Giant Cell Astrocytoma

Interventions: Drug: Placebo
Drug: Everolimus

First Posted Date: 2008-11-13

Last Posted Date: 2016-02-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 117

Registration Number: NCT00789828

Locations: 🇬🇧
Novartis Investigative Site, Bristol, United Kingdom
🇺🇸
Minnesota Epilepsy Group - PA, St. Paul, Minnesota, United States
🇺🇸
Children's Hospital Oakland Hematology/Oncology Dept, Oakland, California, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy